The Black Book of Psychotropic Dosing and Monitoring.
作者信息
DeBattista Charles, Schatzberg Alan F
机构信息
Dr. DeBattista is Professor of psychiatry and director of the Depression Research Clinic in the Department of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine in California. Dr. Schatzberg is Kenneth T. Norris, Jr. professor in the Department of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine in California.
出版信息
Psychopharmacol Bull. 2021 Jan 12;51(1):8-58.
Abstract
摘要
相似文献
1
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2021 Jan 12;51(1):8-58.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2018 Jan 15;48(1):64-153.
3
Single Versus Multiple Daily Dosing Regimens of Psychotropic Drugs for Psychiatric Disorders: A Systematic Review and Meta-Analysis.单剂量与多剂量精神药物治疗精神障碍的比较：系统评价和荟萃分析。
J Clin Psychiatry. 2021 Feb 23;82(2):20r13503. doi: 10.4088/JCP.20r13503.
4
[Psychotropic drugs and behavior].[精神药物与行为]
Ann Pharm Fr. 1998;56(2):75-82.
5
[Psychotropic drugs and behavior].[精神药物与行为]
Bull Acad Natl Med. 1997 Jun-Jul;181(6):1089-101; discussion 1101-4.
6
Higher unit dosage of psychotropic drugs.更高单位剂量的精神药物。
Pharmakopsychiatr Neuropsychopharmakol. 1975 Dec;8(6):345-7. doi: 10.1055/s-0028-1094466.
7
Pharmacokinetics of psychotropic drugs in special populations.精神药物在特殊人群中的药代动力学。
J Clin Psychiatry. 1993 Sep;54 Suppl:50-4; discussion 55-6.
8
Psychotropic drugs and renal failure: translating the evidence for clinical practice.精神药物与肾衰竭：将证据转化为临床实践。
Adv Ther. 2009 Apr;26(4):404-24. doi: 10.1007/s12325-009-0021-x. Epub 2009 May 4.
9
Instructions for clinical and biomarker monitoring in the Summary of Product Characteristics (SmPC) for psychotropic drugs: Overview and applicability in clinical practice.精神药物产品特性摘要（SmPC）中临床和生物标志物监测指南：概述及在临床实践中的适用性
J Psychopharmacol. 2015 Dec;29(12):1248-54. doi: 10.1177/0269881115609016. Epub 2015 Oct 13.
引用本文的文献
1
Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role of lipogenesis and therapeutic consideration.精神疾病中精神药物的代谢并发症：脂肪生成的新作用及治疗考量
World J Psychiatry. 2024 Jun 19;14(6):767-783. doi: 10.5498/wjp.v14.i6.767.
本文引用的文献
1
Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?静脉注射布雷沙诺龙治疗产后抑郁症：它是什么，效果如何，会被使用吗？
Ther Adv Psychopharmacol. 2020 Nov 9;10:2045125320968658. doi: 10.1177/2045125320968658. eCollection 2020.
2
Asenapine Transdermal Patch for the Management of Schizophrenia.阿塞那平透皮贴剂治疗精神分裂症。
Psychopharmacol Bull. 2020 Sep 14;50(4):60-82.
3
Lumateperone: First Approval.卢马替喷：首次批准。
Drugs. 2020 Mar;80(4):417-423. doi: 10.1007/s40265-020-01271-6.
4
Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.比较仑美曲勃与安慰剂和酒石酸唑吡坦延长释放治疗老年失眠障碍：一项 3 期随机临床试验。
JAMA Netw Open. 2019 Dec 2;2(12):e1918254. doi: 10.1001/jamanetworkopen.2019.18254.
5
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.食欲素受体拮抗剂作为治疗精神障碍的新兴疗法。
Neurosci Bull. 2020 Apr;36(4):432-448. doi: 10.1007/s12264-019-00447-9. Epub 2019 Nov 28.
6
Efficacy and safety of cariprazine in the treatment of bipolar disorder.卡利拉嗪治疗双相情感障碍的疗效和安全性。
Expert Opin Pharmacother. 2019 Dec;20(17):2063-2072. doi: 10.1080/14656566.2019.1660319. Epub 2019 Oct 23.
7
Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.地诺孕素治疗产后抑郁症：临床证据与实际考量。
Pharmacotherapy. 2019 Nov;39(11):1105-1112. doi: 10.1002/phar.2331. Epub 2019 Oct 7.
8
Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies.地洛孕素治疗产后抑郁症的疗效：一项随机对照研究的荟萃分析。
Psychiatry Res. 2019 Sep;279:83-89. doi: 10.1016/j.psychres.2019.07.006. Epub 2019 Jul 4.
9
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).依他佐辛鼻喷剂固定剂量联合新型抗抑郁药治疗难治性抑郁症的疗效和安全性：一项随机、双盲、阳性对照研究（TRANSFORM-1）的结果。
Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616-630. doi: 10.1093/ijnp/pyz039.
10
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.新型抗精神病药物的特异性特征：鲁拉西酮、布瑞哌唑、卡利拉嗪和卢美哌隆的临床相关综述。
Eur Neuropsychopharmacol. 2019 Sep;29(9):971-985. doi: 10.1016/j.euroneuro.2019.06.008. Epub 2019 Jun 27.
Zotero 插件